Patents by Inventor Andrew Karl Dilger

Andrew Karl Dilger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FGFR3 inhibitor compounds
    Patent number: 11878976
    Abstract: The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: January 23, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Adedoyin David Abraham, Desta Doro Bume, Kevin Ronald Condroski, Robert Alan Hazlitt, Timothy Scott Kercher, Andrew Terrance Metcalf, Kaveri Balan Urkalan, Shane Michael Walls, Andrew Karl Dilger
  • FGFR3 INHIBITOR COMPOUNDS
    Publication number: 20230095122
    Abstract: The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.
    Type: Application
    Filed: March 3, 2022
    Publication date: March 30, 2023
    Inventors: Adedoyin David ABRAHAM, Desta Doro BUME, Kevin Ronald CONDROSKI, Robert Alan HAZLITT, Timothy Scott KERCHER, Andrew Terrance METCALF, Kaveri Balan URKALAN, Shane Michael WALLS, Andrew Karl DILGER
  • ANTIBODIES AND ANTIGEN BINDING PEPTIDES FOR FACTOR XIA INHIBITORS AND USES THEREOF
    Publication number: 20220220220
    Abstract: The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.
    Type: Application
    Filed: January 7, 2022
    Publication date: July 14, 2022
    Inventors: Joseph M. Luettgen, Lumelle Schneeweis, Ginger Chao Rakestraw, Christina Terragni, Andrew Karl Dilger, Jason Robert Pinckney, Steven Sheriff, Kevin Kish, Yongmi An, William R. Ewing, Stanley Richard Krystek, JR., Aaron Paul Yamniuk